{"id":"W3103606205","doi":"10.1136/jitc-2020-sitc2020.0307","title":"307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Pritzker School of Medicine; American Society of Hematology","keywords":"Vemurafenib; Internal medicine; Medicine; Atezolizumab; Hazard ratio; Oncology; Progression-free survival; Melanoma; Pembrolizumab; Immunotherapy; Cancer research; Cancer; Overall survival; Metastatic melanoma; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003204795,0.0002630069,0.0003215451,0.0000500689,0.00009292835,0.0000882907,0.0001215041,0.0001143253,9.033142e-7],"category_scores_gemma":[0.0001693591,0.0001856868,0.00002306563,0.0001035976,0.000156756,0.0000288655,0.00007049189,0.000194848,6.943601e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001473184,"about_ca_system_score_gemma":0.000182808,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001914675,"about_ca_topic_score_gemma":0.0001731319,"domain_scores_codex":[0.998522,0.0001585946,0.0003221775,0.0004901717,0.0002494952,0.0002575422],"domain_scores_gemma":[0.9993579,0.00002486434,0.0001414649,0.0001974537,0.00005317778,0.0002251621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001265765,0.0004468828,0.8311512,0.0003505335,0.0001638609,0.0004639478,0.006628434,0.0002602345,0.1577966,0.0000936368,0.0001232426,0.001255647],"study_design_scores_gemma":[0.01076583,0.002644567,0.9472007,0.00005656876,0.00007808321,0.00003404655,0.001953762,0.0001168968,0.03594697,0.00008115986,0.0006322903,0.0004891808],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979126,0.0003601926,0.000003363618,0.0004195113,0.00005130564,0.001174184,0.00003619383,0.00001444178,0.00002819814],"genre_scores_gemma":[0.9993359,0.00001385133,0.0001439757,0.0001952841,0.00008965655,0.00005668606,0.0001179809,0.00002587112,0.00002075943],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1218496,"threshold_uncertainty_score":0.7572089,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00991258563327047,"score_gpt":0.2194322897048243,"score_spread":0.2095197040715538,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}